Cargando…

A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder

OBJECTIVE: To assess the efficacy of liraglutide 3.0 mg, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, for binge eating disorder (BED). METHODS: Adults with a body mass index (BMI) ≥ 27 kg/m(2) enrolled in a pilot, 17‐week double‐blind, randomized controlled trial of liraglutide 3.0 mg/day for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allison, Kelly C., Chao, Ariana M., Bruzas, Maija B., McCuen‐Wurst, Courtney, Jones, Elizabeth, McAllister, Cooper, Gruber, Kathryn, Berkowitz, Robert I., Wadden, Thomas A., Tronieri, Jena S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073825/ https://www.ncbi.nlm.nih.gov/pubmed/37034559 http://dx.doi.org/10.1002/osp4.619

Ejemplares similares

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
por: Wadden, Thomas A., et al.
Publicado: (2020)

Effects of Liraglutide on Appetite, Food Preoccupation, and Food Liking: Results of a Randomized Controlled Trial
por: Tronieri, Jena Shaw, et al.
Publicado: (2019)

Binge Eating and Weight Loss Outcomes in Individuals with Type 2 Diabetes: 4-Year Results from the Look AHEAD Study
por: Chao, Ariana M., et al.
Publicado: (2017)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Wadden, Thomas, et al.
Publicado: (2019)

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

Alcohol Intake and Weight Loss during an Intensive Lifestyle Intervention for Adults with Overweight/Obesity and Diabetes
por: Chao, Ariana M., et al.
Publicado: (2018)

Changes in Eating Behaviors and Their Relation to Weight Change 6 and 12 Months After Bariatric Surgery
por: Allison, Kelly C., et al.
Publicado: (2023)

Binge Eating Disorder in Patients with Type 2 Diabetes: Diagnostic and Management Challenges
por: Chevinsky, Jonathan D, et al.
Publicado: (2020)

Dynamic communication for engineers
por: McCuen, Richard H.
Publicado: (1993)

Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations
por: Chao, Ariana M, et al.
Publicado: (2022)

“Last Supper” Predicts Greater Weight Loss Early in Obesity Treatment, but Not Enough to Offset Initial Gains
por: Tronieri, Jena Shaw, et al.
Publicado: (2018)

FORTRAN programming for civil engineers /
por: McCuen, Richard H., 1941-
Publicado: (1975)

Hydrologic analysis and design /
por: McCuen, Richard H., 1941-
Publicado: (1998)

Numerical Analysis for Engineers
por: Ayyub, Bilal, et al.
Publicado: (2015)

Exposure–response analyses of liraglutide 3.0 mg for weight management
por: Wilding, J. P. H., et al.
Publicado: (2016)

Weight Bias Internalization Is Negatively Associated With Weight-Related Quality of Life in Persons Seeking Weight Loss
por: Walsh, Olivia A., et al.
Publicado: (2018)

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
por: Blackman, A, et al.
Publicado: (2016)

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials
por: O'Neil, Patrick M., et al.
Publicado: (2017)

Placebo response in binge eating disorder
por: Jacobs-Pilipski, M Joy, et al.
Publicado: (2007)

Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
por: Overgaard, Rune V., et al.
Publicado: (2016)

Features of Addiction in Binge-Eating Disorder: Considerations for Screening and Treatment
por: Paul, Alexandra, et al.
Publicado: (2023)

Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
por: Wharton, Sean, et al.
Publicado: (2019)

Short- and Long-Term Changes in Health-Related Quality of Life with Weight Loss: Results from a Randomized Controlled Trial
por: Pearl, Rebecca L., et al.
Publicado: (2018)

The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
por: Mancini, Marcio C., et al.
Publicado: (2017)

Impact of binge eating disorder on functional impairment and work productivity in an adult community sample in the United States
por: Pawaskar, Manjiri, et al.
Publicado: (2017)

Processes and pathways to binge eating: development of an integrated cognitive and behavioural model of binge eating
por: Burton, Amy L., et al.
Publicado: (2019)

THE TOLL OF BINGE EATING ON AGING: THE PHYSICAL FUNCTIONING OF OLDER WOMEN WITH WEEKLY BINGE EATING
por: Hooper, Savannah, et al.
Publicado: (2022)

Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management
por: Kolotkin, R. L., et al.
Publicado: (2016)

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
por: Albaker, Waleed, et al.
Publicado: (2021)

Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting
por: Ko, Hae-Jin, et al.
Publicado: (2022)

A psychometric analysis and revalidation of the Yale-Brown Obsessive Compulsive Scale modified for Binge Eating in adults with binge eating disorder
por: Yee, Karen, et al.
Publicado: (2019)

Binge eating and psychostimulant addiction
por: Blanco-Gandia, M Carmen, et al.
Publicado: (2021)

The sequential binge: a new therapeutic approach for binge eating
por: Neveu, Remi, et al.
Publicado: (2015)

Binge eating behavior in a sample of Lebanese Adolescents: Correlates and Binge Eating Scale validation
por: Mina, Anthony, et al.
Publicado: (2021)

Retention, engagement, and binge‐eating outcomes: Evaluating feasibility of the Binge‐Eating Genetics Initiative study
por: Flatt, Rachael E., et al.
Publicado: (2022)

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada
por: Wharton, Sean, et al.
Publicado: (2020)

Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program
por: Wharton, Sean, et al.
Publicado: (2020)

Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery
por: Wharton, Sean, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jhfaga7nk30tdbt76user804ag